Purpose: To support new Investigators in Ovarian Cancer through ongoing participation in the DF/HCC Ovarian Cancer SPORE, to provide opportunities for one on one mentorship with senior DF/HCC SPORE investigators and support of the development of new Ovarian Cancer investigators. 

Eligibility:  
1) Faculty Appointment at Massachusetts-based institutions or other Ovarian Cancer SPORE institutions in the United States
2) A current or imminent Faculty appointment at the home institution (instructor, assistant professor, preferred).   Senior research fellows / or post docs may be considered only with prior approval of the CEP committee)
3) Clinical, population or lab-based researchers are all eligible.  
4) Underserved minority investigators are strongly encouraged to apply.

One to 3 awards of $50,000 each direct costs will be awarded, renewable on a one-year basis for a total of 2 years

Submission Deadline: 5:00 p.m.- Friday, July 7, 2023
Award date:  August 1, 2023 – July 31, 2024

Note: Funding will be for a 12-month period. Project must be achievable in the above 12-month period, with awarded funds spent in full.

Selection Criteria: a review committee will make the award based on these criteria:

• Career development plan
• Scientific quality of the proposed laboratory or clinical study
• Qualifications of the investigators and the environment
• Potential for future translation to clinical application in ovarian cancer
• Relevance to patients with ovarian cancer
• Contribution to the DF/HCC Ovarian Cancer SPORE
• Potential for extramural funding

Application Materials: e-mail the following materials in a single PDF file to Dr. Cesar Castro at:  Castro.cesar@mgh.harvard.edu

1)     Project title and names of candidate and primary mentor
2)     Abstract of proposed research (up to 300 words maximum)
3)     Research description (not to exceed 5 pages (excluding literature cited which is up to one page max):  Specific aims, Background, Methods, Translational goals, Timeline, Anticipated Core utilization, Biostatistical description should be included in the 5 page total.   References, Human Subjects issues (including IRB consent as appropriate) and animal welfare should be addressed outside the 5 page limit.  If there is a clinical trial component, the research description should indicate whether therapeutic agents are FDA approved, and how they are to be supplied
4)     One page of career development plan
5)     Budget and Justification (one page maximum).
6)     Biosketch of Candidate and mentor, in current NIH format (up to 5 pages) with other support pages
7)     Cover letter from the Divisional or Departmental Chief, indicating approval and support of the proposal.
8)     Appendix, including up to one page of preliminary data and 2 relevant reprints.

Please send application to:  Dr. Cesar Castro, Director of the CEP: castro.cesar@mgh.harvard.edu

Purpose: To support pilot projects that take maximum advantage of new research opportunities within the DF/HCC Ovarian Cancer SPORE, to advance and foster high quality, novel, early-phase research, and to move these research projects from a pilot stage to a level where external funding for more mature research is possible

Eligibility: 
1) Massachusetts-based institutions as well as other Ovarian Cancer SPORE institutions in the United States
2) Faculty members at all levels (instructor, assistant professor, associate professor, or professor)
Clinical, population or lab-based researchers are all eligible. Underserved minority investigators are strongly encouraged to apply.

Up to 2 awards of $60,000 direct costs will be awarded, renewable on a one-year basis for a total of 2 years

Submission Deadline: 5:00 p.m.- Friday, July 7, 2023

Award date:  August 1, 2023 – July 31, 2024

Note: Funding will be for a 12-month period. Project must be achievable in the above 12-month period, with awarded funds spent in full.

Selection Criteria: a review committee will make the award based on these criteria:
▪ Innovation of scientific questions to ovarian cancer
▪ Scientific quality of the proposed laboratory or clinical study
▪ Qualifications of the investigators and the environment
▪ Potential for future translation to clinical application in ovarian cancer
▪ Relevance to patients with ovarian cancer
▪ Contribution to the DF/HCC Ovarian Cancer SPORE
▪ Potential for extramural funding

Application Materials: e-mail the following materials in a single PDF file to:  KatianneE_Poulin@dfci.harvard.edu

1) Project title and names of research and clinical/translational co-leaders if applicable 
2) Abstract of proposed research (up to 300 words maximum)
3) Research description (not to exceed five pages (excluding literature cited which is up to one page max):  Specific aims, Background, Methods, Translational goals, Timeline, Anticipated Core utilization, Biostatistical description, and Human Subjects issues (including IRB consent as appropriate).  If there is a clinical trial component, the research description should indicate whether therapeutic agents are FDA approved, and how they are to be supplied
4) Appendix, including preliminary data and relevant reprints.
5) Budget and Justification (one page maximum).
6) Biosketch of Principal and any co-Investigators, in current NIH format (up to 5 pages)
7) Other support page in NIH format (if not already listed in Biosketch)
8) Cover letter from the Divisional or Departmental Chief, indicating approval and support of the proposal.

For any questions, please contact Ursula Matulonis, MD, co-PI of the DF/HCC Ovarian cancer SPORE and Director of the DRP at email address:   ursula_matulonis@dfci.harvard.edu. 

**Please send the application to:  KatianneE_Poulin@dfci.harvard.edu